» Articles » PMID: 38753250

Molecular Mechanism of Yangshen Maidong Decoction in the Treatment of Chronic Heart Failure Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations

Overview
Date 2024 May 16
PMID 38753250
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic heart failure (CHF) is a complex multifactorial clinical syndrome leading to abnormal cardiac structure and function. The severe form of this ailment is characterized by high disability, high mortality, and morbidity. Worldwide, 2-17% of patients die at first admission, of which 17-45% die within 1 year of admission and >50% within 5 years. Yangshen Maidong Decoction (YSMDD) is frequently used to treat the deficiency and pain of the heart. The specific mechanism of action of YSMDD in treating CHF, however, remains unclear. Therefore, a network pharmacology-based strategy combined with molecular docking and molecular dynamics simulations was employed to investigate the potential molecular mechanism of YSMDD against CHF. The effective components and their targets of YSMDD and related targets of CHF were predicted and screened based on the public database. The network pharmacology was used to explore the potential targets and possible pathways that involved in YSMDD treated CHF. Molecular docking and molecular dynamics simulations were performed to elucidate the binding affinity between the YSMDD and CHF targets. Screen results, 10 main active ingredients, and 6 key targets were acquired through network pharmacology analysis. Pathway enrichment analysis showed that intersectional targets associated pathways were enriched in the Prostate cancer pathway, Hepatitis B pathway, and C-type lectin receptor signaling pathways. Molecular docking and molecular dynamics simulations analysis suggested 5 critical active ingredients have high binding affinity to the 5 key targets. This research shows the multiple active components and molecular mechanisms of YSMDD in the treatment of CHF and offers resources and suggestions for future studies.

References
1.
Chen L, Wei N, Jiang Y, Yuan C, Xu L, Li J . Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS. J Ethnopharmacol. 2022; 303:116035. DOI: 10.1016/j.jep.2022.116035. View

2.
Zhang H, Zhang L, Yin K, Zhang M, Hao Y, Zhou H . Analysis of Function Role and Long Noncoding RNA Expression in Chronic Heart Failure Rats Treated with Hui Yang Jiu Ji Decoction. J Healthc Eng. 2023; 2023:7438567. PMC: 9873466. DOI: 10.1155/2023/7438567. View

3.
Gheorghiade M, Abraham W, Albert N, Greenberg B, OConnor C, She L . Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006; 296(18):2217-26. DOI: 10.1001/jama.296.18.2217. View

4.
West R, Liang L, Fonarow G, Kociol R, Mills R, OConnor C . Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail. 2011; 13(9):945-52. PMC: 3157970. DOI: 10.1093/eurjhf/hfr064. View

5.
Towbin J . Inherited cardiomyopathies. Circ J. 2014; 78(10):2347-56. PMC: 4467885. DOI: 10.1253/circj.cj-14-0893. View